Date:2/7/2013

oved Phase 2 clinical trials and Phase 1b/2a trials. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking sta
'/>"/>

SOURCE Oramed Pharmaceuticals Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Free Research Report on Ford Motor Co., Pfizer, Inc., Barclays Bank PLC, General Electric Co. and PowerShares QQQ Trust
2. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
3. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
4. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
5. Southern Home Medical Once Again Reduces The Companys Issued And Outstanding Preferred Shares
6. As Deadline Approaches, Practice Fusion Shares Meaningful Use Stories
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
9. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
10. iMD Companies Inc. receives shares of Positive Solutions
11. Silence Therapeutics - Admission of Shares and Board Update